- Home
- PFO vs IMUX Comparison
PFO vs IMUX Comparison
Compare PFO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFO
- IMUX
- Stock Information
- Founded
- PFO 1991
- IMUX 2016
- Country
- PFO United States
- IMUX United States
- Employees
- PFO N/A
- IMUX N/A
- Industry
- PFO Finance Companies
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- PFO Finance
- IMUX Health Care
- Exchange
- PFO Nasdaq
- IMUX Nasdaq
- Market Cap
- PFO 123.7M
- IMUX 110.8M
- IPO Year
- PFO N/A
- IMUX N/A
- Fundamental
- Price
- PFO $9.02
- IMUX $1.11
- Analyst Decision
- PFO
- IMUX Strong Buy
- Analyst Count
- PFO 0
- IMUX 5
- Target Price
- PFO N/A
- IMUX $13.20
- AVG Volume (30 Days)
- PFO 31.8K
- IMUX 931.7K
- Earning Date
- PFO 01-01-0001
- IMUX 11-07-2024
- Dividend Yield
- PFO 6.51%
- IMUX N/A
- EPS Growth
- PFO N/A
- IMUX N/A
- EPS
- PFO N/A
- IMUX N/A
- Revenue
- PFO N/A
- IMUX N/A
- Revenue This Year
- PFO N/A
- IMUX N/A
- Revenue Next Year
- PFO N/A
- IMUX N/A
- P/E Ratio
- PFO N/A
- IMUX N/A
- Revenue Growth
- PFO N/A
- IMUX N/A
- 52 Week Low
- PFO $6.90
- IMUX $0.97
- 52 Week High
- PFO $8.51
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- PFO 32.67
- IMUX 36.96
- Support Level
- PFO $9.05
- IMUX $1.02
- Resistance Level
- PFO $9.18
- IMUX $1.28
- Average True Range (ATR)
- PFO 0.11
- IMUX 0.08
- MACD
- PFO -0.02
- IMUX -0.00
- Stochastic Oscillator
- PFO 3.33
- IMUX 35.29
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end investment company. Its primary investment objective is to produce high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.